5. (Four Times Amended) An isolated polypeptide comprising a sequence of amino acids selected from the group consisting of:

(a) amino acids 848-1278 of a type F botulinum toxin (SEQ ID NO: 1)

(b) amino acids 848-991 of a type F botulinum toxin (SEQ ID NO: 2)

(c) amino acids 992-1135 of a type F botulinum toxin (SEQ ID NO: 3), and;

(d) amino acids 1136-1278 of a type F botulinum toxin (SEQ ID NO: 4)

G1

6. (Four Times Amended) An isolated polypeptide comprising a dimer of the sequences selected from the group consisting of:

But H3

(a) amino acids 848-1278 of a type F botulinum toxin (SEQ ID NO: 1)

(b) amino acids 848-991 of a type F botulinum toxin (SEQ ID NO: 2)

(c) amino acids 992-1135 of a type F botulinum toxin (SEQ ID NO: 3), and

(d) amino acids 1136-1278 of a type F botulinum toxin (SEQ ID NO: 4)

7. (Four Times Amended) A polypeptide composition comprising:

G2

(1) an isolated polypeptide according to claim 5; and

(2) an isolated polypeptide that facilitates or enhances purification of the composition.

But H4 G3

8. (Three Times Amended) A polypeptide composition comprising an isolated fusion protein of a sequence of amino acids selected from the group consisting of SEQ

Rwt H4 G3 cont

ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4, fused to a polypeptide that facilitates or enhances purification of the composition.

Rwt H7

12. (Three Times Amended) A vaccine comprising a pharmaceutically acceptable carrier and a polypeptide according to claim 5.

13. (Amended) A recombinant DNA encoding a polypeptide according to claim 5.

14. (Amended) A method of producing a polypeptide according to claim 5 comprising the steps of:

G4 Rwt H8

(a) expressing in a host cell a DNA encoding a fusion protein, said protein being a fusion of (i) a fragment or derivative of a type F botulinum toxin, and (ii) a moiety adapted to bind to a chromatography column,

(b) obtaining from said host cell an extract comprising the fusion protein, and

(c) purifying the fusion protein using a chromatography column.

Rwt H9 G5

17. (Amended) A method of making a pharmaceutical composition comprising:

(a) expressing in a host cell a DNA encoding a fusion protein, said protein being a polypeptide of claim 8,

(b) obtaining from said host cell an extract comprising the fusion protein,

(c) purifying the fusion protein using chromatography column,

(d) incorporating the purified fusion protein into a pharmaceutical composition.

19. (Three Times Amended) A pharmaceutical composition comprising:

(a) a fusion protein, said protein being a fusion of (i) a polypeptide as described in claim 5, and (ii) a polypeptide that binds to a chromatography column; and

(b) a pharmaceutically acceptable carrier.

21. (Three Times Amended) A pharmaceutical composition according to Claim 19 wherein the fusion protein comprises a polypeptide that binds to an affinity chromatography column.

26. (Amended) An isolated fusion protein comprising (1) a sequence of amino acids selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4, and (2) a polypeptide that facilitates or enhances purification of the fusion protein.

28. (Twice Amended) The fusion protein of claim 26 wherein said *C. botulinum* amino acid sequence consists of SEQ ID NO: 1.

30. (Twice Amended) The fusion protein of claim 26 wherein said amino acid sequence comprises at least one amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4.